South Africa is a study in contrasts. And the 2026 public health agenda is no exception. Breakthrough HIV prevention medicine ...

Once exclusively a treatment for diabetes, GLP-1 medications have gone mainstream — forcing restaurants to adjust to changing ...

A single-judge bench of Delhi high court had allowed Dr Reddy’s to continue manufacturing and exporting semaglutide to ...

Pharmaceutical companies have raised prices on hundreds of drugs so far this month despite federal efforts to rein in drug ...

After a lackluster first half of 2025, healthcare stocks staged a comeback, posting the best performance among the 11 S&P 500 ...

Strive Compounding Pharmacy alleges the two pharma companies are coordinating an effort to restrict compounded access.

For the quarter ended December 31, 2025, the SMA outperformed the Index on both a gross- and net-of-fees basis due to ...

NVO shares jump 9.1% as early U.S. prescriptions for oral Wegovy show strong first-week demand after its early January launch ...

Despite ushering in the current GLP-1 era, Novo Nordisk has fallen behind its chief rival Eli Lilly, which has exceeded the ...

Eli Lilly is tackling a high-growth market: weight loss. The company’s weight loss portfolio brought in $10 billion in the ...

GLP-1 agonist injections, although originally developed to treat type 2 diabetes, have changed how we approach obesity.1 The two main types now in use—semaglutide (Wegovy), produced by Novo Nordisk, ...